國家衛生研究院 NHRI:Item 3990099045/10415
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 967782      線上人數 : 814
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10415


    題名: The role of pre-treatment plasma Epstein-Barr virus (EBV) DNA as a predictive biomarker of induction chemotherapy for stage IVA or IVB nasopharyngeal carcinoma (NPC) patients - A Subgroup Analysis on Taiwan Cooperative Oncology Group (TCOG) 1303 study
    作者: Kao, HF;Hsiao, CF;Lai, SC;Wang, CW;Ko, JY;Lo, PJ;Lee, TJ;Liu, TW;Hong, RL
    貢獻者: Institute of Population Health Sciences;National Institute of Cancer Research
    摘要: Background: Pre-treatment plasma EBV DNA is considered as a prognostic biomarker for NPC patients. Whether the pre-treatment EBV DNA could be a biomarker guiding the treatment for advanced NPC patients warrants investigation. Methods: TCOG 1303 was a phase III trial comparing induction chemotherapy (IC) followed by concurrent chemoradiation (CCRT) versus CCRT alone in stage IVA or IVB NPC patients. In both arms, radiotherapy would be delivered with weekly cisplatin (30mg/m2). For patients in IC arm, chemotherapy with mitomycin C, epirubicin, cisplatin, 5-fluorouracil, and leucovorin were administered for 3 cycles before the CCRT. The primary endpoint was disease free survival. Pre-treatment plasma EBV DNA was analyzed. Results: From September 2003 to August 2009, 479 patients were enrolled. The pre-treatment plasma EBV DNA were collected from 264 patients. The median follow-up were 66 months. The median of plasma EBV DNA was 7862.5 copies/mL. 135 pts were grouped in EBV DNA = 8000 copies/mL (EBV-high). High plasma EBV DNA is statistically significant with larger tumor size (p . Conclusions: Pre-treatment plasma EBV DNA cannot be a biomarker of induction MEPFL for stage IVA or IVB NPC patients. The biology role of pre-treatment EBV DNA should be explored.
    日期: 2016-10
    關聯: Annals of Oncology. 2016 Oct;27(Suppl.6 ):Meeting Abstract 973P.
    Link to: http://dx.doi.org/10.1093/annonc/mdw376.25
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000393913000069
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85081593474
    顯示於類別:[蕭金福] 會議論文/會議摘要
    [劉滄梧] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000393913000069.pdf74KbAdobe PDF342檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋